Skip to main content
SpringerLink
Log in

Lumateperone in schizophrenia: a profile of its use

  • Adis Drug Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Oral lumateperone (Caplyta®) is an atypical antipsychotic indicated for the treatment of schizophrenia in adults in the USA. As a mechanistically novel agent that selectively and simultaneously modulates serotonin, dopamine, and glutamate neurotransmission, it offers a new option for the management of this severe and debilitating mental disorder. Across three phase 2 or 3 studies in patients with an acute exacerbation of schizophrenia, double-blind treatment with lumateperone 42 mg/day for 4–6 weeks significantly improved psychotic symptoms and global disease severity compared with placebo. Additionally, open-label treatment with lumateperone for up to 1 year was associated with continuous improvements in psychotic symptoms in patients with stable schizophrenia switched from standard-of-care antipsychotics. Lumateperone therapy is generally well tolerated, with a placebo-like and comparatively favourable safety profile with respect to motor, metabolic and cardiovascular issues.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Stępnicki P, Kondej M, Kaczor AA. Current concepts and treatments of schizophrenia. Molecules. 2018;23(8):2087.

    Article  PubMed Central  Google Scholar 

  2. Chong HY, Teoh SL, Wu DB, et al. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016;12:357–73.

    PubMed  PubMed Central  Google Scholar 

  3. Patel KR, Cherian J, Gohil K, et al. Schizophrenia: overview and treatment options. Pharm Ther. 2014;39(9):638–45.

    Google Scholar 

  4. Divac N, Prostran M, Jakovcevski I, et al. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int. 2014;2014:656370.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Snyder G, Davis R, Dutheil S, et al. Unique pharmacology and clinical evidence supporting the antidepressant therapeutic potential of lumateperone [abstract]. Biol Psychiatry. 2018;83(9 Suppl 1):S378.

    Article  Google Scholar 

  6. Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Correll CU, Solmi M, Veronese N, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16:163–80.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Remington G, Foussias G, Fervaha G, et al. Treating negative symptoms in schizophrenia: an update. Curr Treat Options Psychiatry. 2016;3:133–50.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Hill SK, Bishop JR, Palumbo D, et al. Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Rev Neurother. 2010;10(1):43–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. McCutcheon RA, Krystal JH, Howes OD. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry. 2020;19(1):15–33.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Uno Y, Coyle JT. Glutamate hypothesis in schizophrenia. Psychiatry Clin Neurosci. 2019;73(5):204–15.

    Article  PubMed  Google Scholar 

  12. Snyder GL, Vanover KE, Zhu H, et al. Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission. Psychopharmacology. 2015;232(3):605–21.

    Article  CAS  PubMed  Google Scholar 

  13. Intra-Cellular Therapies Inc. Caplyta (lumateperone) capsules, for oral use: US prescribing information. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf. Accessed 14 Sep 2020.

  14. Vanover KE, Davis RE, Zhou Y, et al. Dopamine D2 receptor occupancy of lumateperone (ITI-007): a positron emission tomography study in patients with schizophrenia. Neuropsychopharmacology. 2019;44(3):598–605.

    Article  CAS  PubMed  Google Scholar 

  15. Davis RE, Vanover KE, Zhou Y, et al. ITI-007 demonstrates brain occupancy at serotonin 5-HT2A and dopamine D2 receptors and serotonin transporters using positron emission tomography in healthy volunteers. Psychopharmacology. 2015;232(15):2863–72.

    Article  CAS  PubMed  Google Scholar 

  16. Vanover KE, O'Gorman C, Correll CU, et al. Lumateperone (ITI-007): a novel investigational agent with broad therapeutic potential across multiple neuropsychiatric disorders [abstract no. P.1.g.038]. Eur Neuropsychopharmacol. 2017;27(Suppl 4):S660–1.

    Article  Google Scholar 

  17. Center for Drug Evaluation and Research. Application number: 209500Orig1s000. Multi-discipline review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209500Orig1s000MultidisciplineR.pdf. Accessed 14 Sept 2020.

  18. Lieberman JA, Davis RE, Correll CU, et al. ITI-007 for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial. Biol Psychiatry. 2016;79(12):952–61.

    Article  CAS  PubMed  Google Scholar 

  19. Correll CU, Davis RE, Weingart M, et al. Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2020;77(4):349–58.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Vanover KE, Kane JM, Satlin A, et al. Efficacy and safety of lumateperone tosylate 42 mg in the treatment of schizophrenia: a pooled analysis of randomized controlled trials [poster no. 201]. In: 58th Annual Meeting of the American College of Neuropsychopharmacology. 2019.

  21. Tamminga CA, Vanover K, Weingart M. The efficacy of lumateperone 42 mg in the treatment of schizophrenia: a pooled analysis of phase 2 and 3 randomized controlled trials [abstract + poster no. P7-067]. In: 172nd Annual Meeting of the American Psychiatric Association. 2019.

  22. Satlin A, Vanover K, Durgam S, et al. Additional results from a 12-month open-label safety study of lumateperone (ITI-007) in patients with stable symptoms of schizophrenia [abstract no. W203 + poster]. In: 58th Annual Meeting of the American College of Neuropsychopharmacology. 2019.

  23. Vanover K, O'Gorman C, Glass S, et al. Favorable clinical safety profile for lumateperone (ITI-007): switching from standard-of-care antipsychotic therapy in patients with schizophrenia [abstract no. T189 + poster]. Neuropsychopharmacology. 2017;43(Suppl 1):S416–7.

    Google Scholar 

  24. Davis R, Dmitrienko A, Glass S, et al. Lumateperone (ITI-007): favorable safety profile in an open label safety switching study from standard-of-care antipsychotic therapy in patients with schizophrenia. Schizophr Bull. 2018;44(Suppl 1):S236–7.

    Article  PubMed Central  Google Scholar 

  25. O'Gorman C, Vanover KE, Correll CU, et al. The safety and tolerability of lumateperone (ITI-007) for patients with schizophrenia: combined results from large placebo-controlled studies [abstract]. In: 170th Annual Meeting of the American Psychiatric Association. 2017.

  26. Kane JM, Vanover KE, Durgam S, et al. Efficacy and safety of lumateperone tosylate 42 mg in the treatment of schizophrenia: a pooled analysis of phase 2 and 3 studies. Eur Neuropsychopharmacol. 2019;29(Suppl 6):S453–4.

    Article  Google Scholar 

  27. Vanover K, Satlin A, Durgam S, et al. Favorable long-term safety profile of lumateperone IITI-007): results from a 12 month open label safety study for lumateperone in patients with stable symptoms of schizophrenia [abstract no. S117]. Schizophr Bull. 2019;45(Suppl 2):S351.

    Article  PubMed Central  Google Scholar 

Download references

Acknowledgements

The manuscript was reviewed by: J. R. Brašić, Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA; A. C. Yang,Institute of Brain Science and Digital Medicine Center, National Yang-Ming University, Taipei, Taiwan. During the peer review process, Intra-Cellular Therapies Inc., the marketing-authorization holder of lumateperone, was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    James E. Frampton

Authors
  1. James E. Frampton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James E. Frampton.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and Conflict of interest

J.E. Frampton is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability

Not applicable.

Additional information

Enhanced material for this Adis Drug Q&A can be found at https://doi.org/10.6084/m9.figshare.12965078.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Frampton, J.E. Lumateperone in schizophrenia: a profile of its use. Drugs Ther Perspect 36, 477–484 (2020). https://doi.org/10.1007/s40267-020-00780-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-020-00780-4

Search

Navigation